• Profile
Close

Alirocumab efficacy and safety in patients with hypercholesterolemia and with or without clinical atherosclerotic cardiovascular disease: Pooled analysis of 10 ODYSSEY randomized trials

Canadian Journal of Cardiology Oct 06, 2017

Jones P, et al. - This study entails an appraisal of alirocumab (ALI) for safety and lipid-lowering efficacy among patients with or without clinical atherosclerotic cardiovascular disease (ASCVD). In both patient groups, ALI demonstrated good tolerability, generally. Treatment with ALI afforded substantial reductions in LDL-C levels and allowed greater LDL-C goal achievement, compared with controls.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay